Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Upgraded by Wall Street Zen

Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday, Wall Street Zen reports.

Separately, Weiss Ratings cut Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.50.

Acrivon Therapeutics Price Performance

NASDAQ ACRV opened at $1.86 on Monday. Acrivon Therapeutics has a 1 year low of $1.27 and a 1 year high of $3.56. The stock has a market capitalization of $79.71 million, a PE ratio of -0.99 and a beta of 1.91. The business’s 50-day moving average is $1.95 and its 200 day moving average is $1.78.

Acrivon Therapeutics (NASDAQ:ACRV) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07. As a group, equities research analysts anticipate that Acrivon Therapeutics will post -1.76 earnings per share for the current year.

Insider Activity

In related news, CEO Peter Blume-Jensen sold 14,036 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $2.21, for a total transaction of $31,019.56. Following the transaction, the chief executive officer owned 2,230,052 shares in the company, valued at $4,928,414.92. The trade was a 0.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 18,253 shares of company stock worth $38,850 in the last 90 days. 10.50% of the stock is owned by insiders.

Institutional Trading of Acrivon Therapeutics

A hedge fund recently bought a new stake in Acrivon Therapeutics stock. Spark Investment Management LLC acquired a new stake in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 28,300 shares of the company’s stock, valued at approximately $50,000. Spark Investment Management LLC owned 0.07% of Acrivon Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its Acrivon Predictive Precision Oncology (AP3) platform to identify tumor characteristics that may predict a patient’s response to specific targeted therapies.

Acrivon’s lead program is ACR-368, an orally administered small-molecule inhibitor designed to target the checkpoint kinase 1 (CHK1) and WEE1 proteins, which help regulate tumor-cell replication and DNA damage responses.